New agents for the prevention of opportunistic infections in haematopoietic stem cell transplant recipients

Gianna Zuccotti, Lynne Strasfeld, David M. Weinstock

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Over the past three decades, autologous and allogeneic haematopoietic stem cell transplants (HSCTs) have become effective treatments for a variety of malignant and nonmalignant conditions. Patients who undergo HSCT receive high doses of chemotherapy and/or radiation that induce a prolonged period of profound immunodeficiency, placing them at high risk for infection from a panoply of opportunistic organisms. Although supportive treatment for these patients has markedly improved, 10 - 20% of allogeneic HSCT recipients will ultimately succumb to infection. Joint guidelines to prevent opportunistic infection were released in 2000 by the Centers for Disease Control, the Infectious Diseases Society of America, and the American Society of Blood and Marrow Transplantation; however, treatment decisions for these patients are often based on limited studies or depend on institution-specific transplant protocols and antibiotic resistance patterns. This paper will discuss new agents for preventing bacterial, fungal and viral infections in HSCT recipients.

Original languageEnglish (US)
Pages (from-to)1669-1679
Number of pages11
JournalExpert Opinion on Pharmacotherapy
Volume6
Issue number10
DOIs
StatePublished - Aug 2005
Externally publishedYes

Fingerprint

Opportunistic Infections
Hematopoietic Stem Cells
Transplants
Mycoses
Virus Diseases
Centers for Disease Control and Prevention (U.S.)
Microbial Drug Resistance
Infection
Bacterial Infections
Therapeutics
Joints
Transplantation
Bone Marrow
Transplant Recipients
Guidelines
Radiation
Drug Therapy

Keywords

  • Infection
  • Prophylaxis
  • Stem cell transplant

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

New agents for the prevention of opportunistic infections in haematopoietic stem cell transplant recipients. / Zuccotti, Gianna; Strasfeld, Lynne; Weinstock, David M.

In: Expert Opinion on Pharmacotherapy, Vol. 6, No. 10, 08.2005, p. 1669-1679.

Research output: Contribution to journalArticle

@article{1429f19ecc3048aa8d3fee2e48daaf01,
title = "New agents for the prevention of opportunistic infections in haematopoietic stem cell transplant recipients",
abstract = "Over the past three decades, autologous and allogeneic haematopoietic stem cell transplants (HSCTs) have become effective treatments for a variety of malignant and nonmalignant conditions. Patients who undergo HSCT receive high doses of chemotherapy and/or radiation that induce a prolonged period of profound immunodeficiency, placing them at high risk for infection from a panoply of opportunistic organisms. Although supportive treatment for these patients has markedly improved, 10 - 20{\%} of allogeneic HSCT recipients will ultimately succumb to infection. Joint guidelines to prevent opportunistic infection were released in 2000 by the Centers for Disease Control, the Infectious Diseases Society of America, and the American Society of Blood and Marrow Transplantation; however, treatment decisions for these patients are often based on limited studies or depend on institution-specific transplant protocols and antibiotic resistance patterns. This paper will discuss new agents for preventing bacterial, fungal and viral infections in HSCT recipients.",
keywords = "Infection, Prophylaxis, Stem cell transplant",
author = "Gianna Zuccotti and Lynne Strasfeld and Weinstock, {David M.}",
year = "2005",
month = "8",
doi = "10.1517/14656566.6.10.1669",
language = "English (US)",
volume = "6",
pages = "1669--1679",
journal = "Expert Opinion on Pharmacotherapy",
issn = "1465-6566",
publisher = "Informa Healthcare",
number = "10",

}

TY - JOUR

T1 - New agents for the prevention of opportunistic infections in haematopoietic stem cell transplant recipients

AU - Zuccotti, Gianna

AU - Strasfeld, Lynne

AU - Weinstock, David M.

PY - 2005/8

Y1 - 2005/8

N2 - Over the past three decades, autologous and allogeneic haematopoietic stem cell transplants (HSCTs) have become effective treatments for a variety of malignant and nonmalignant conditions. Patients who undergo HSCT receive high doses of chemotherapy and/or radiation that induce a prolonged period of profound immunodeficiency, placing them at high risk for infection from a panoply of opportunistic organisms. Although supportive treatment for these patients has markedly improved, 10 - 20% of allogeneic HSCT recipients will ultimately succumb to infection. Joint guidelines to prevent opportunistic infection were released in 2000 by the Centers for Disease Control, the Infectious Diseases Society of America, and the American Society of Blood and Marrow Transplantation; however, treatment decisions for these patients are often based on limited studies or depend on institution-specific transplant protocols and antibiotic resistance patterns. This paper will discuss new agents for preventing bacterial, fungal and viral infections in HSCT recipients.

AB - Over the past three decades, autologous and allogeneic haematopoietic stem cell transplants (HSCTs) have become effective treatments for a variety of malignant and nonmalignant conditions. Patients who undergo HSCT receive high doses of chemotherapy and/or radiation that induce a prolonged period of profound immunodeficiency, placing them at high risk for infection from a panoply of opportunistic organisms. Although supportive treatment for these patients has markedly improved, 10 - 20% of allogeneic HSCT recipients will ultimately succumb to infection. Joint guidelines to prevent opportunistic infection were released in 2000 by the Centers for Disease Control, the Infectious Diseases Society of America, and the American Society of Blood and Marrow Transplantation; however, treatment decisions for these patients are often based on limited studies or depend on institution-specific transplant protocols and antibiotic resistance patterns. This paper will discuss new agents for preventing bacterial, fungal and viral infections in HSCT recipients.

KW - Infection

KW - Prophylaxis

KW - Stem cell transplant

UR - http://www.scopus.com/inward/record.url?scp=23844502097&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=23844502097&partnerID=8YFLogxK

U2 - 10.1517/14656566.6.10.1669

DO - 10.1517/14656566.6.10.1669

M3 - Article

C2 - 16086653

AN - SCOPUS:23844502097

VL - 6

SP - 1669

EP - 1679

JO - Expert Opinion on Pharmacotherapy

JF - Expert Opinion on Pharmacotherapy

SN - 1465-6566

IS - 10

ER -